Borna Biopharma

Borna Biopharma is a prominent Iranian biotechnology company specializing in the development and large-scale production of recombinant proteins and biosimilars. Established to provide high-tech therapeutic solutions for chronic conditions, the company focuses on neurology and infectious diseases. Its commercial portfolio includes Ziferon, a biosimilar interferon beta-1a for multiple sclerosis, and Pegaferon, a pegylated interferon used in the treatment of viral hepatitis. Borna Biopharma operates advanced manufacturing facilities that comply with international Good Manufacturing Practice (GMP) standards. The company is recognized for its expertise in protein purification and pegylation technologies within the Middle Eastern pharmaceutical market. By producing complex biologics domestically, Borna Biopharma significantly improves patient access to essential life-science treatments in the region.